UK MHRA’s IVD Chief Warns About ‘Wrong’ Deviation From EU Medtech Regulations
Executive Summary
Ahead of the MHRA’s release of its post-UK regulatory consultation findings, the agency’s Mike Messenger outlined ongoing thought processes for how regulation should drive efficiencies in diagnostics.
You may also be interested in...
If You Build It, Will They Come? Vital That UK MHRA Creates Right Environment For Medtechs
The Medicines and Medical Devices Act presses the UK to regulate in such a way that makes the market attractive for industry and investment. Medtech manufacturers insist the MHRA must strike the right balance as it brings its ‘plan for a new agency’ to life, said the ABHI’s Phil Brown, in the second of a two-part industry view of UK medtech’s regulatory future.
UKCA Marking Debate Moves To Next Level: All Eyes On The MHRA
The MHRA is under pressure to deliver a new sovereign devices regulatory system in the tightest of timelines for the post-Brexit UK market. It has had no lack of support in this endeavor from system users, but industry is now keen to see the regulator deliver on its two-year plan issued in 2021, says the ABHI’s Phil Brown, in this first part of a two-part industry view of future UK needs.
UK Device Safety To Be Enhanced By Patient Safety Commissioner
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.